Overview

Casodex vs Placebo in Non-Metastatic Early Prostate Cancer

Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
0
Participant gender:
Male
Summary
The purpose of this trial is to study the effect of adjuvant or immediate hormonal therapy, versus placebo, in subjects who have either undergone a primary therapy (principally radical prostatectomy or radiotherapy) or who were otherwise to be managed by watchful waiting.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Scandinavian Prostate Cancer Group
Treatments:
Bicalutamide
Criteria
Inclusion Criteria:

- Clinical diagnosis of non-metastatic cancer of the prostate gland

- Patient to be 18 years and above

Exclusion Criteria:

- Previous systemic therapy for prostate cancer

- Previous history of another form of cancer (not prostate) within 5 years of study
start.